Merck reported strong Q1 performance with significant growth in key areas, but lowered full-year guidance due to COVID-19-related challenges, particularly in patient access and animal health. Management remains optimistic about a return to normal operations in the coming quarters, which may help stabilize investor sentiment. However, the immediate outlook is cautiously negative given the guidance downgrade.

[-1]